HC Wainwright Analysts Raise Earnings Estimates for TRDA

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Entrada Therapeutics in a research report issued on Monday, March 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.12) per share for the quarter, up from their prior estimate of ($1.20). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q2 2026 earnings at ($1.30) EPS, Q3 2026 earnings at ($1.12) EPS, Q4 2026 earnings at ($0.96) EPS, FY2026 earnings at ($4.49) EPS, Q1 2027 earnings at ($0.80) EPS, Q2 2027 earnings at ($0.72) EPS, Q3 2027 earnings at ($0.79) EPS, Q4 2027 earnings at ($0.87) EPS and FY2027 earnings at ($3.18) EPS.

Several other equities analysts have also commented on TRDA. Wall Street Zen raised shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Roth Mkm set a $13.00 price target on shares of Entrada Therapeutics in a report on Thursday, November 6th. Oppenheimer initiated coverage on shares of Entrada Therapeutics in a research note on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price objective for the company. Guggenheim raised Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.50.

Entrada Therapeutics Price Performance

Shares of NASDAQ:TRDA opened at $12.50 on Thursday. The firm has a market capitalization of $478.50 million, a P/E ratio of -3.61 and a beta of -0.12. The business’s 50-day moving average is $10.99 and its 200 day moving average is $8.62. Entrada Therapeutics has a 1 year low of $4.93 and a 1 year high of $12.93.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.38. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $7.41 million.

Institutional Trading of Entrada Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC boosted its holdings in Entrada Therapeutics by 9.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after purchasing an additional 1,560 shares during the period. Alliancebernstein L.P. boosted its stake in shares of Entrada Therapeutics by 7.1% in the 3rd quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock valued at $141,000 after buying an additional 1,620 shares during the period. Great Lakes Advisors LLC grew its position in shares of Entrada Therapeutics by 5.5% during the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock worth $445,000 after buying an additional 2,239 shares in the last quarter. Intech Investment Management LLC increased its stake in shares of Entrada Therapeutics by 15.7% during the second quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock worth $119,000 after buying an additional 2,397 shares during the period. Finally, Quadrature Capital Ltd lifted its stake in Entrada Therapeutics by 13.5% in the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock worth $209,000 after acquiring an additional 2,424 shares during the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Key Entrada Therapeutics News

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $20 price target on TRDA, highlighting material upside vs. the current share price and providing bullish analyst support for investors. Article Title
• Positive Sentiment: HC Wainwright slightly raised its Q1 2026 EPS forecast (less negative: from ($1.20) to ($1.12)), a modest near-term improvement that can be read as a small positive signal about expense or timing assumptions. Article Title
• Neutral Sentiment: HC Wainwright published a full set of quarterly and FY2027 forecasts (Q1–Q4 2026/2027 and FY2026/2027) — useful for modeling but largely informational until company results or guidance confirm assumptions. Article Title
• Neutral Sentiment: Reported short-interest data is effectively zero/ambiguous (0 shares reported), so it does not appear to be a material driver of intraday moves or a source of short-squeeze risk. Article Title
• Negative Sentiment: HC Wainwright lowered several near-term EPS estimates — notably cutting FY2026 from ($4.21) to ($4.49) and trimming Q2–Q4 2026 and Q3 2026 estimates — signaling larger expected losses next year and raising short-term execution/financing concerns. Article Title

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.